RxDoctor Payments Data

Frances Saenz

Family · Salisbury, MDNPI 1881466340

Payments from drug & device makers

$1,086in general payments, 2019–2025

Across 40 payments — averaging $27.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$180
  • Boehringer Ingelheim$159
  • Exact Sciences$112
  • Lilly USA, LLC$73
  • Harmony Biosciences LLC$67
  • Alkermes, Inc.$65
  • plus $430 from 15 others

What the payments were for

  • Food & beverage$1,086100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,086 in reported general payments places this provider in the 70th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$26,795
Medicare patients
96
Services billed
560

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide14$25,541
OzempicSemaglutide17$23,131
JardianceEmpagliflozin16$18,038
XareltoRivaroxaban12$12,020
Spiriva RespimatTiotropium Bromide11$5,457
Rosuvastatin Calcium50$1,681
Albuterol Sulfate HfaAlbuterol Sulfate50$1,477
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$1,413
Atorvastatin Calcium66$1,344
Amlodipine Besylate97$665
Losartan Potassium57$581
Fluticasone Propionate50$570
Montelukast Sodium20$566
Potassium Chloride18$542
Levocetirizine Dihydrochloride17$499

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$180$48,67231 claims
Boehringer IngelheimJardiance, Spiriva Respimat$159$23,49427 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,843 family providers in Maryland.

Other family in Salisbury

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →